Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 10-2018 | 07-2018 | 04-2018 | 01-2018 | 10-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,334 | -5,030 | N/A | -15,148 | -9,914 |
| Depreciation Amortization | 153 | 50 | N/A | 129 | 79 |
| Accounts payable and accrued liabilities | 2,088 | 1,126 | N/A | 548 | -139 |
| Other Working Capital | -8,366 | -1,585 | N/A | 31,253 | -2,397 |
| Other Operating Activity | -539 | -773 | 0 | -269 | 664 |
| Operating Cash Flow | $-14,998 | $-6,212 | $N/A | $16,513 | $-11,707 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -786 | -565 | N/A | -343 | -161 |
| Investing Cash Flow | $-786 | $-565 | $N/A | $-343 | $-161 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -104 | -52 | N/A | -101 | -49 |
| Common Stock Issued | 87,836 | 5,000 | N/A | 9,100 | 9,100 |
| Financing Cash Flow | $87,732 | $4,948 | $N/A | $8,999 | $9,051 |
| Exchange Rate Effect | -1,887 | -1,156 | N/A | 2,559 | -5 |
| Beginning Cash Position | 51,055 | 51,055 | N/A | 30,950 | 30,950 |
| End Cash Position | 121,116 | 48,070 | N/A | 58,678 | 28,128 |
| Net Cash Flow | $70,061 | $-2,985 | $N/A | $27,728 | $-2,822 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,998 | -6,212 | N/A | 16,513 | -11,707 |
| Capital Expenditure | -786 | -565 | N/A | -343 | -161 |
| Free Cash Flow | -15,784 | -6,777 | 0 | 16,170 | -11,868 |